Clene Prepares Briefing Book for Potential ALS Treatment CNM-Au8(R)
Clene (NASDAQ: CLNN) and its subsidiary Clene Nanomedicine Inc. prepare a briefing book for potential ALS treatment CNM-Au8(R). The book aims to address FDA comments and demonstrate the therapy's potential, offering hope to ALS patients.
This news matters because it highlights the progress of a potential treatment for ALS, a devastating neurodegenerative disease. If successful, CNM-Au8(R) could offer hope to ALS patients and their families, addressing an unmet medical need and improving quality of life.
